![European Crohn's and Colitis Organisation (ECCO) Congress 2019, Bella Center, Copenhagen, Copenhagen (Hovedstaden), Denmark | eMedEvents European Crohn's and Colitis Organisation (ECCO) Congress 2019, Bella Center, Copenhagen, Copenhagen (Hovedstaden), Denmark | eMedEvents](https://d3p2qewzsoh75c.cloudfront.net/uploads/conferences/logo/200/european_crohn_s_and_colitis_organisation_ecco_1538201630.jpeg)
European Crohn's and Colitis Organisation (ECCO) Congress 2019, Bella Center, Copenhagen, Copenhagen (Hovedstaden), Denmark | eMedEvents
![14th Congress of ECCO - Congresses & Events - Events - Events & Newsroom - The European Society of Pathology 14th Congress of ECCO - Congresses & Events - Events - Events & Newsroom - The European Society of Pathology](https://www.esp-pathology.org/_Resources/Persistent/e63342e3c9fd510184d2343b4232c16550758458/MASTER_ECCO%2719%20Web%20banner_150x100%20%28002%29.jpg)
14th Congress of ECCO - Congresses & Events - Events - Events & Newsroom - The European Society of Pathology
![Gianluca Pellino on Twitter: "@EuroSurg 1 poster on at 11 ECCO Congress in Amsterdam. We are spreading! https://t.co/VnibnJrvlu" / Twitter Gianluca Pellino on Twitter: "@EuroSurg 1 poster on at 11 ECCO Congress in Amsterdam. We are spreading! https://t.co/VnibnJrvlu" / Twitter](https://pbs.twimg.com/media/CdvS3_kWoAALoxM.jpg)
Gianluca Pellino on Twitter: "@EuroSurg 1 poster on at 11 ECCO Congress in Amsterdam. We are spreading! https://t.co/VnibnJrvlu" / Twitter
![High Infliximab Trough Levels Are Associated With Low Risk of Relapse When Switching to Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease, Suggests New Data Presented at ECCO 2022 Virtual Congress High Infliximab Trough Levels Are Associated With Low Risk of Relapse When Switching to Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease, Suggests New Data Presented at ECCO 2022 Virtual Congress](https://mms.businesswire.com/media/20220217006014/en/1364385/23/Celltrionhealthcare-CI.jpg)
High Infliximab Trough Levels Are Associated With Low Risk of Relapse When Switching to Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease, Suggests New Data Presented at ECCO 2022 Virtual Congress
![12th Congress of ECCO - Congresses & Events - Events - Events & Newsroom - The European Society of Pathology 12th Congress of ECCO - Congresses & Events - Events - Events & Newsroom - The European Society of Pathology](https://www.esp-pathology.org/_Resources/Persistent/ac53b796218c5b837763c09492b2107fa2791497/170907_v2_ECCO%2717%20Web%20banner_150x100.jpg)